Home > Resources > Whitepapers > Digital maturity inan age of digital excitement

Digital maturity inan age of digital excitement

July 5, 2018

It is obvious that digital technologies hold the promise of solving many besetting healthcare problems. Yet if we are too positive, we run the risk of being uncritical and perhaps exploited by unscrupulous marketing, or even marketing equally caught up in the uncritical excitement. How, then, do we rise above this and become more mature? Scoping and understanding digital maturity and its value is the goal of this short paper.

Spotlight

CB Solutions, LLC.

CB Solutions is an environmental and energy services provider, and a company that is dedicated to the renewal of the environment, through the exceptional achievement of innovative products created over many years of research and development. The combined experience of our staffs, of over 60 years of product development and environmental consulting, has allowed us to offer products which are second to none in a very competitive market. It is that competitive market, and ever-increasing regulations, that has given us the drive to achieve the exceptional.

OTHER WHITEPAPERS

State of the Global Biotech Landscape

whitePaper | November 22, 2022

Over the last five years, the global biotech and pharmaceutical landscape has witnessed continued growth. The analysis period encompasses a unique timeframe including the global COVID-19 pandemic.

Accelerating the Biomanufacturing Revolution

whitePaper | February 11, 2022

The biomanufacturing revolution is here. Recent advancements in the field of synthetic biology have enabled significant cost reductions in foundational bioengineering unit operations such as DNA synthesis and sequencing.

Enabling the Future of Cell & Gene Therapies through Non Proprietary Patient-Owned Data Collection

whitePaper | March 16, 2021

Cell and gene therapies have emerged as a new treatment paradigm, and with them has come the potential to alter the course of many rare diseases. In many cases, there is an opportunity to correct the underlying dysfunction with a one-time administration of a therapy and provide either a functional cure or a substantial improvement in health outcomes. In other cases, long term symptom relief will be the primary therapeutic objective. Some of these indications may require more than one dose to achieve continued symptom relief and scientists and companies are working on technologies that will enable the use of a repeat dose.

Taking the Lead on Lab Cybersecurity

whitePaper | October 21, 2022

Just as thieves developed a new interest in explosives following the 1861 invention of the combination lock—and the concurrent rise in the popularity of bank vaults.

Asia Pacific – Clinical trial landscape

whitePaper | November 28, 2022

The Asia-Pacific area is home to around two thirds of the world’s population and has a wide range of cultural, political, economic, and other factors that affect vaccine development, use, and registration.

The US Bioeconomy

whitePaper | April 14, 2022

In the nearly 50 years since the first genetic engineering experiments, the United States has become the world’s biotechnology powerhouse,